Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

short term income and recurring revenue streams from a successful product launch in the future.

Regulatory strategy

CeNeS preferred strategy is for a partner to be involved in the key decisions regarding regulatory filing strategies both in Europe and in United States. The strategy in the USA is clear. The strong data obtained from the most recent Phase III study validates the proposed product profile of M6G and strengthens CeNeS position with potential North American partners. Registration could be achieved in the USA in 2009 after conducting two Phase III studies to the requirements of the FDA. It is important to note that the quality and robustness of the clinical data produced by the current study significantly reduces the risk for the development of M6G by enabling optimal trial design and the selection of endpoints in the remaining Phase III studies.

In Europe the narrow failure to achieve statistical significance with the second chosen primary endpoint of incidence and severity of nausea (p=0.052 not p<0.050) offers three options:

1) Pursue a filing application in certain European countries with the comprehensive clinical data package that CeNeS has assembled. 2) Further strengthen the European package by conducting an additional European Phase III study which would complete in 2008 with product filing in 2009. 3) Use the USA Phase III trials to support the European application, potentially with a global partner.

CeNeS will continue to discuss the above strategies with regulatory consultants and potential partners.

Neil Clark, Chief Executive of CeNeS commented "The ongoing analysis of the Phase III results further confirms our belief in the excellent potential of M6G as a novel product for post- operative pain. The quality and breadth of the data contained in this large study supports M6G's anticipated product profile.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... June 22, 2007 /PRNewswire/ -- MAP,Pharmaceuticals, Inc. today ... its Unit Dose Budesonide (UDB) pediatric asthma therapy,clinical ... Lutfi Kirdar,Convention and Exhibition Center in Istanbul, Turkey. ... and safety,of a novel submicron particle formulation of ...
... Announces Bioinformatics Partnership with,Illumina , BEYOND GENOME ... a leading developer of lab and data ... announced that,it has penned an agreement with ... participant in IlluminaConnect, a,bioinformatics software program established ...
Cached Medicine Technology:MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2GenoLogics Announces Bioinformatics Partnership with Illumina 2GenoLogics Announces Bioinformatics Partnership with Illumina 3
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... Oxygen", as it is known by researchers at the Norwegian ... is gained on the pitch thanks to their new system ... the Journal of Sports Medicine and has enjoyed ... improve the players, sprint, jump and endurance. , "With ...
... near manufacturing industries, a breath of air may ... location, finds a recent study involving a Kansas ... of geology at Kansas State University, along with ... School of Public Health and Department of Environmental ...
... Measurement of pressure within the eye, or intraocular pressure (IOP), ... in patients with glaucoma are believed to be related to ... to the optic nerve and vision. The clinical assessment ... daytime hours. In a new study, parents using the ...
... Steven Reinberg HealthDay Reporter , TUESDAY, March ... who have psychiatric disorders, especially post-traumatic stress disorder, are ... narcotic painkillers, a new study finds. Use of ... Vicodin, can become addictive and cause more serious problems, ...
... (HealthDay News) -- Most stroke patients undergo both CT and ... rising costs of stroke care in the United States, a ... from more than 600,000 patients diagnosed with stroke between 1999 ... of the patients who had MRI scans also had CT ...
... (HealthDay News) -- When it comes to wine, a new study ... on many consumers. The professionals seem to have a much ... State University explained. As a result, wine experts are able to ... people just can,t taste. "What we found is that the ...
Cached Medicine News:Health News:1 more 'player' on the pitch thanks to a new training method 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 3Health News:Home measurement of eye pressure in children may improve management of glaucoma 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 3Health News:Brain Scans Overused on U.S. Stroke Patients, Study Says 2Health News:Wine Ratings May Be Meaningless for Most People 2
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Medicine Products: